About Hubei Biocause Heilen Pharmaceutical Company

The company was listed on the Shenzhen Stock Exchange GEM on December 22, 2021. It was founded in 1995 and currently has more than 900 employees. The company is a post-doctoral pharmaceutical industry base in Hubei Province, a high-tech enterprise in Hubei Province, the pharmacy teaching base of Tongji Medical College of Huazhong University of Science and Technology, the fourth batch of hidden champion enterprises in Hubei Province, one of the six key insurance and supply enterprises in the fight against COVID-19 in Hubei Province in 2020, and one of the top 6 manufacturers of ibuprofen APIs in the world. It is a leading global nonsteroidal anti-inflammatory API enterprise. The company is mainly engaged in R&D, production and sales of chemical raw materials (including intermediates) and pharmaceutical products, and can provide contract R&D and production services (CDMO) according to customer needs. The company's main products are divided into two categories: APIs and formulations. Among them, APIs can be subdivided into non-steroidal anti-inflammatory, cardiovascular, anti-tumor, and anticholinergic drugs. Corporate honors: High-tech enterprises in Hubei Province in 2016 and 2021, China's top 20 CDMO enterprises in 2021, China's GMP certificate obtained in 2007, etc.